PVCT Financial Facts
Net loss applicable to common shareholders: -8.86MInvestment income: 318
See Full Income Statement
Warrant liability: 3.34M
Total Liabilities And Stockholders' Equity: 10.69M
See Full Balance Sheet
Provectus Biopharma (PVCT) Earnings
|
Expand Research on PVCT
Next EPS Date | 5/7/24 | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | N/A | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | N/A | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
5/7/24 | Q124 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
2/28/24 | Q423 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
11/10/23 | Q323 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
11/13/23 | Q323 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
8/9/23 | Q223 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
8/28/23 | Q223 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
8/21/23 | Q223 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
5/9/23 | Q123 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |